Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
Background: Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can guide antiplatelet therapy in ACS patients. Objec...
में बचाया:
मुख्य लेखकों: | , , , , , , |
---|---|
स्वरूप: | पुस्तक |
प्रकाशित: |
Centro de Investigaciones y Publicaciones Farmaceuticas,
2014-09-01T00:00:00Z.
|
विषय: | |
ऑनलाइन पहुंच: | Connect to this object online. |
टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
इंटरनेट
Connect to this object online.3rd Floor Main Library
बोधानक: |
A1234.567 |
---|---|
प्रति 1 | उपलब्ध |